Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia

Saddichha, S., Manjunatha, N., Ameen, S. and Akhtar, S. (2008) Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatrica Scandinavica, 117 5: 342-347. doi:10.1111/j.1600-0447.2008.01158.x


Author Saddichha, S.
Manjunatha, N.
Ameen, S.
Akhtar, S.
Title Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia
Journal name Acta Psychiatrica Scandinavica   Check publisher's open access policy
ISSN 0001-690X
1600-0447
Publication date 2008-05-01
Sub-type Article (original research)
DOI 10.1111/j.1600-0447.2008.01158.x
Open Access Status Not yet assessed
Volume 117
Issue 5
Start page 342
End page 347
Total pages 6
Place of publication Hoboken, NJ, United States
Publisher Wiley-Blackwell Publishing
Language eng
Formatted abstract
Objective: There have been innumerable advances in the pharmacotherapy of schizophrenia, but problems have emerged hand-in-glove, such as the presence of treatment-emergent glucose intolerance and frank diabetes mellitus (DM).

Method: Medication-naïve patients with schizophrenia (n = 99) underwent baseline fasting and 2 h post-prandial plasma glucose measurements repeated after 6 weeks after randomization to receive olanzapine, risperidone or haloperidol. The results were compared with a matched healthy control group.

Results: A significant difference (P = 0.002) in baseline 2 h post-prandial blood sugar (PPBS) was noted between the control group and the treatment group along with a significant increase in weight (P < 0.001), fasting blood sugar (P = 0.01) and 2 h PPBS (P < 0.001) from baseline to endpoint between the groups. A statistical significance in the incidence of DM at endpoint by the WHO criteria (10.1%) was also noted.

Conclusion: Male patients with schizophrenia are liable to develop DM. Antipsychotic treatment leads to the development of DM in a significant 10.1% within 6 weeks.
Keyword Antipsychotics
Diabetes
First-episode psychosis
Haloperidol
Olanzapine
Risperidone
Schizophrenia
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 51 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 64 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 21 Sep 2016, 00:03:14 EST by System User on behalf of Learning and Research Services (UQ Library)